Literature DB >> 10478136

Demonstration of distinct antigenic profiles of small B-cell lymphomas by paraffin section immunohistochemistry.

P J Kurtin1, K S Hobday, S Ziesmer, B L Caron.   

Abstract

The immunoperoxidase technique was used with antibodies against B-cell-associated antigens, including CD20, CD79a, CD10, CD23, CD43, cyclin D1, bcl-2, and kappa and lambda immunoglobulin light chains on formalin-fixed and B5-fixed tissue sections of follicular, small lymphocytic, mantle cell, and marginal zone lymphomas. Results obtained with paraffin section immunohistochemistry for CD20, CD10, CD23, and kappa and lambda light chains were compared with results obtained with flow cytometry or frozen section immunohistochemistry. Cells in all of the lymphoma types were positive for CD20 and CD79a. The antigenic profiles of the B-cell lymphomas demonstrated in paraffin sections were lymphoma type distinctive. Intrafollicular lymphocytes in follicular lymphomas were positive for CD10 and bcl-2. Small lymphocytic lymphomas expressed CD43 and CD23 and were negative for CD10 and cyclin D1. Mantle cell lymphomas characteristically expressed CD43 and cyclin D1 and were negative for CD23 and CD10. Marginal zone lymphomas were negative for CD23, CD10, and cyclin D1. All of the antibodies performed better in B5-fixed tissues, but formalin-fixed tissue immunophenotypes were always similar to those obtained on the B5-fixed tissue. These results were possible using well-fixed tissue, various antigen retrieval strategies, paraffin section reactive primary antibodies, and sensitive detection systems. Paraffin section immunohistochemistry on sections of routinely fixed tissue can be used similarly to flow cytometry and frozen section immunohistochemistry when classifying the lymphomas of small B lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10478136     DOI: 10.1093/ajcp/112.3.319

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  13 in total

Review 1.  Ectopic lymphoid organogenesis: a fast track for autoimmunity.

Authors:  C M Weyand; P J Kurtin; J J Goronzy
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

2.  Expression of the chemokine receptor gene, CCR8, is associated With DUSP22 rearrangements in anaplastic large cell lymphoma.

Authors:  Xiaoming Xing; Thomas J Flotte; Mark E Law; Anthony J Blahnik; Wee-Joo Chng; Gaofeng Huang; Ryan A Knudson; Rhett P Ketterling; Julie C Porcher; Stephen M Ansell; Jagmohan Sidhu; Ahmet Dogan; Andrew L Feldman
Journal:  Appl Immunohistochem Mol Morphol       Date:  2015-09

Review 3.  Current treatment strategy and new agents in mantle cell lymphoma.

Authors:  Michinori Ogura
Journal:  Int J Hematol       Date:  2010-06-08       Impact factor: 2.490

4.  Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group.

Authors:  David J Inwards; Paul A S Fishkin; David W Hillman; David W Brown; Stephen M Ansell; Paul J Kurtin; Rafael Fonseca; Roscoe F Morton; Michael H Veeder; Thomas E Witzig
Journal:  Cancer       Date:  2008-07-01       Impact factor: 6.860

5.  Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.

Authors:  Wei Ding; Betsy R LaPlant; Timothy G Call; Sameer A Parikh; Jose F Leis; Rong He; Tait D Shanafelt; Sutapa Sinha; Jennifer Le-Rademacher; Andrew L Feldman; Thomas M Habermann; Thomas E Witzig; Gregory A Wiseman; Yi Lin; Erik Asmus; Grzegorz S Nowakowski; Michael J Conte; Deborah A Bowen; Casey N Aitken; Daniel L Van Dyke; Patricia T Greipp; Xin Liu; Xiaosheng Wu; Henan Zhang; Charla R Secreto; Shulan Tian; Esteban Braggio; Linda E Wellik; Ivana Micallef; David S Viswanatha; Huihuang Yan; Asher A Chanan-Khan; Neil E Kay; Haidong Dong; Stephen M Ansell
Journal:  Blood       Date:  2017-04-19       Impact factor: 22.113

6.  Aberrant expression of the dendritic cell marker TNFAIP2 by the malignant cells of Hodgkin lymphoma and primary mediastinal large B-cell lymphoma distinguishes these tumor types from morphologically and phenotypically similar lymphomas.

Authors:  Svetlana Kondratiev; Sekhar Duraisamy; Christine L Unitt; Michael R Green; Geraldine S Pinkus; Margaret A Shipp; Jeffery L Kutok; Ronny I Drapkin; Scott J Rodig
Journal:  Am J Surg Pathol       Date:  2011-10       Impact factor: 6.394

7.  Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies.

Authors:  David A Wada; Mark E Law; Eric D Hsi; David J Dicaudo; Linglei Ma; Megan S Lim; Aieska de Souza; Nneka I Comfere; Roger H Weenig; William R Macon; Lori A Erickson; Nazan Ozsan; Stephen M Ansell; Ahmet Dogan; Andrew L Feldman
Journal:  Mod Pathol       Date:  2010-12-17       Impact factor: 7.842

8.  Clinicopathologic features of CDK6 translocation-associated B-cell lymphoproliferative disorders.

Authors:  Dong Chen; Mark E Law; Jason D Theis; Jeffrey D Gamez; Lynn B Caron; Julie A Vrana; Ahmet Dogan
Journal:  Am J Surg Pathol       Date:  2009-05       Impact factor: 6.394

9.  PAX5-positive T-cell anaplastic large cell lymphomas associated with extra copies of the PAX5 gene locus.

Authors:  Andrew L Feldman; Mark E Law; David J Inwards; Ahmet Dogan; Rebecca F McClure; William R Macon
Journal:  Mod Pathol       Date:  2010-01-29       Impact factor: 7.842

10.  ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes.

Authors:  Edgardo R Parrilla Castellar; Elaine S Jaffe; Jonathan W Said; Steven H Swerdlow; Rhett P Ketterling; Ryan A Knudson; Jagmohan S Sidhu; Eric D Hsi; Shridevi Karikehalli; Liuyan Jiang; George Vasmatzis; Sarah E Gibson; Sarah Ondrejka; Alina Nicolae; Karen L Grogg; Cristine Allmer; Kay M Ristow; Wyndham H Wilson; William R Macon; Mark E Law; James R Cerhan; Thomas M Habermann; Stephen M Ansell; Ahmet Dogan; Matthew J Maurer; Andrew L Feldman
Journal:  Blood       Date:  2014-06-03       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.